Immunotherapeutic strategies in breast cancer: a clinical update
Open accessAbstract
Immunotherapy has been incorporated into the standard of care for a wide range of malignancies. The study of tumor‐infiltrating lymphocytes has emphasized the importance of the host antitumor immune response in the natural history of breast cancer. Recent clinical trials have used immunotherapeutic approaches to augment this response and improve outcomes for patients with breast cancer. Here, we review several current clinical trial data that indicate checkpoint blockade may mediate clinically significant responses.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
By targeting these receptors, immune checkpoint blockade lessens CD8+ T-cell exhaustion and is approved for some triple-negative breast cancer patients.
“ICB mitigates CD8+ T-cell exhaustion by targeting these receptors and is approved for a subset of triple-negative BC patients (27).”
ICB has shown only modest efficacy in breast cancer.
“ICB has revolutionized the treatment of multiple malignancies. However, its efficacy in BC has been modest (27,70).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · see citing works
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160 · see citing works
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · see citing works
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · see citing works
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · see citing works
Cortazar, P., Zhang, L., Untch, M., Mehta, K. M., Costantino, J. P., Wolmark, N., Bonnefoi, H. R., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,777 · see citing works
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350 · see citing works
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071 · see citing works
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270 · see citing works
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., den Eynden, G. V., Baehner, F. L., Penault-Llorca, F. M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,142 · see citing works
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,736 · see citing works
Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30904-x · Cited by 2,157 · see citing works
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789 · see citing works
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb‐Esfahani, S., Kronenwett, R., Hanusch, C. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,761 · see citing works
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Eenoo, F. V., Rouas, G., Francis, P. A., Crown, J. P., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,634 · see citing works
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477 · see citing works
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric‐Bernstam, F., Qiao, N., Wu, Y., Harrington, S. M., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akçakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,394 · see citing works
Adams, S., Gray, R. J., Demaria, S., Goldstein, L. J., Perez, E. A., Shulman, L. N., Martino, S., Wang, M., Jones, V. E., Saphner, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0491 · Cited by 1,301 · see citing works
Schmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Henschel, V., Molinero, L., Chui, S. Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30689-8 · Cited by 1,216 · see citing works
Mittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M. L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31953-x · Cited by 1,083 · cited 13× · see citing works
“The recently published IMpassion031 trial is a phase III double‐ blind randomized trial evaluating the efficacy and safety of atezolizumab or placebo plus nab‐paclitaxel followed by doxorubicin and cyclophosphamide in patients with untreated stage II–III TNBC.(44) One hundred and sixty‐five patients were assigned to t…”
MethodResultInfluentialLoi, S., Drubay, D., Adams, S., Pruneri, G., Francis, P. A., Lacroix-Triki, M., Joensuu, H., Dieci, M. V., Badve, S., Demaria, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01010 · Cited by 893 · see citing works
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.215 · Cited by 890 · see citing works
Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
Ali, H. R., Provenzano, E., Dawson, S., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, L., Dunn, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu191 · Cited by 773 · see citing works
Dirix, L. Y., Takács, I., Jérusalem, G., Nikolinakos, P. G., Arkenau, H., Forero, A., Boccia, R. V., Lippman, M. E., Somer, R. A., Šmakal, M., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4537-5 · Cited by 748 · see citing works
Nanda, R., Liu, M. C., Yau, C., Shatsky, R., Pusztai, L., Wallace, A., Chien, A. J., Forero-Torres, A., Ellis, E., Han, H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6650 · Cited by 710 · see citing works
Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B. V., Blohmer, J., Grischke, E., Furlanetto, J., Tesch, H., Hanusch, C. A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz158 · Cited by 698 · see citing works
Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness
Welch, H. G., Prorok, P. C., O’Malley, A. J., & Kramer, B. S. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600249 · Cited by 698 · see citing works
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
Plitas, G., Konopacki, C., Wu, K., Bos, P. D., Morrow, M., Putintseva, E. V., Chudakov, D. M., & Rudensky, A. Y. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.032 · Cited by 695 · see citing works
Self-citationSalgado, R., Denkert, C., Campbell, C., Savas, P. S., Nuciforo, P. G., Aura, C. M., de Azambuja, E., Eidtmann, H., Ellis, C. E., Baselga, J. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0830 · Cited by 605 · see citing works
Differences in Breast Cancer Survival by Molecular Subtypes in the United States
Howlader, N., Cronin, K. A., Kurian, A. W., & Andridge, R. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0627 · Cited by 605 · see citing works
Leukocyte composition of human breast cancer
Ruffell, B., Au, A., Rugo, H. S., Esserman, L. J., Hwang, E. S., & Coussens, L. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104303108 · Cited by 481 · see citing works
Loi, S., Giobbie‐Hurder, A., Gombos, A., Bachelot, T., Hui, R., Curigliano, G., Campone, M., Biganzoli, L., Bonnefoi, H. R., Jérusalem, G., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30812-x · Cited by 472 · see citing works
Schmid, P., Salgado, R., Park, Y. H., Muñoz-Couselo, E., Kim, S. B., Sohn, J., Im, S.-A., Foukakis, T., Kuemmel, S., Dent, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.072 · Cited by 413 · see citing works
Current Landscape of Immunotherapy in Breast Cancer: A Review
Adams, S., Gatti-Mays, M. E., Kalinsky, K., Korde, L. A., Sharon, E., Amiri-Kordestani, L., Bear, H., McArthur, H. L., Frank, E., Perlmutter, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7147 · Cited by 384 · see citing works
Immunological differences between primary and metastatic breast cancer
Székely, B., Bossuyt, V., Li, X., Wali, V. B., Patwardhan, G. A., Frederick, C., Silber, A. L. M., Park, T., Harigopal, M., Pelekanou, V., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy399 · Cited by 357 · see citing works
Cimino‐Mathews, A., Thompson, E. D., Taube, J. M., Ye, X., Yao, L., Meeker, A. K., Xu, H., Sharma, R. B., Lecksell, K., Cornish, T. C., et al. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.09.003 · Cited by 336 · see citing works
Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review
Underwood, J. C. E. (1974) · British Journal of Cancer · doi:10.1038/bjc.1974.233 · Cited by 309 · see citing works
Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival
Morris, L. G. T., Riaz, N., Desrichard, A., Şenbabaoğlu, Y., Hakimi, A. A., Makarov, V., Reis-Filho, J. S., & Chan, T. A.-T. (2016) · Oncotarget · doi:10.18632/oncotarget.7067 · Cited by 297 · see citing works
Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
Efremova, M., Rieder, D., Klepsch, V., Charoentong, P., Finotello, F., Hackl, H., Hermann‐Kleiter, N., Löwer, M., Baier, G., Krogsdam, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02424-0 · Cited by 295 · see citing works
Park, J. H., Jonas, S. F., Bataillon, G., Criscitiello, C., Salgado, R., Loi, S., Viale, G., Lee, H. J., Dieci, M. V., Kim, S. B., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz395 · Cited by 249 · see citing works
Manohar, S., Kompotiatis, P., Thongprayoon, C., Cheungpasitporn, W., Herrmann, J., & Herrmann, S. M. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy105 · Cited by 197 · see citing works
Why have breast cancer mortality rates declined?
Narod, S. A., Iqbal, J., & Miller, A. B. (2015) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2015.03.002 · Cited by 194 · see citing works
Verkaik, N. S., Esveldt, R. E., van Heemst, D., Brüggenwirth, H. T., Hoeijmakers, J. H. J., Zdzienicka, M. Z., & van Gent, D. C. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200203)32:3 · Cited by 189 · see citing works
Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer
Karn, T., Jiang, T., Hatzis, C., Sänger, N., El‐Balat, A., Rody, A., Holtrich, U., Becker, S., Bianchini, G., & Pusztai, L. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2140 · Cited by 153 · see citing works
Hutchinson, K. E., Yost, S. E., Chang, C., Johnson, R. M., Carr, A. R., McAdam, P. R., Halligan, D. L., Chang, C.-C., Schmolze, D. B., Liang, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1773 · Cited by 114 · see citing works
Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis
Jiang, T., Shi, W., Wali, V. B., Pongor, L. S., Li, C., Lau, R., Győrffy, B., Lifton, R. P., Symmans, W. F., Pusztai, L., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002193 · Cited by 80 · see citing works
Kim, A., Lee, S. J., Kim, Y. K., Park, W. Y., Park, D. Y., Kim, J. Y., Lee, C. H., Gong, G., Huh, G. Y., & Choi, K. U. (2017) · Scientific Reports · doi:10.1038/s41598-017-11905-7 · Cited by 79 · see citing works
Yuan, C., Liu, Z., Yu, Q., Wang, X., Bian, M., Yu, Z., & Yu, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-50898-3 · Cited by 77 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Gomes-Santos, I. L., Amoozgar, Z., Kumar, A. S., Ho, W. W., Roh, K., Talele, N. P., Curtis, H., Kawaguchi, K., Jain, R. K., & Fukumura, D. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0499 · Cited by 181 · see citing works
Singla, R. K., Wang, X., Gundamaraju, R., Joon, S., Tsagkaris, C., Behzad, S., Khan, J., Gautam, R. K., Goyal, R., Rakmai, J., et al. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2097196 · Cited by 47 · see citing works
Lu, Y., Bi, J., Li, F., Wang, G., Zhu, J., Jin, J., & Liu, Y. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.942049 · Cited by 8 · see citing works
Jiang, S., Bu, X., Tang, D., Yan, C., Huang, Y. Y., & Fang, K. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.783026 · Cited by 5 · see citing works
Tumor Microcirculation: Abnormalities and Normalization
Fukumura, D. (2025) · Physiology in health and disease · doi:10.1007/978-3-031-99609-2_13 · Cited by 1 · see citing works
- Authors
- Zhang, J. Q., & Plitas, G.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Plitas, George
- Venue
- Journal of Surgical Oncology
- Publisher
- Wiley
- Published
- 2020-11-06
- Volume
- 123
- Issue
- 3
- Pages
- 710-717
- ISSN
- 0022-4790 (ISSN-L)
- 1096-9098
- PMC
- PMC7889634
- OpenAlex
- W3096044212
- Cited by
- 6
- References
- 51
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 3 · 2021: 1
- FWCI
- 0.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Surgical Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Advanced Breast Cancer Therapies
- Keywords
- breast cancer, immunotherapy, tumor-infiltrating lymphocytes, immune checkpoint blockade, antitumor immunity, clinical trials, host immune response
- MeSH terms
- Immune Checkpoint Inhibitors, Breast Neoplasms, Female, Humans, Immunotherapy, Randomized Controlled Trials as Topic, Lymphocytes, Tumor-Infiltrating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
